Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory First in Human Phase I Clinical and Pharmacokinetic Study of Intra-tumoral Administration of BO-112 in Adult Patients With Aggressive Solid Tumors, With an Extension Cohort in Combination With Anti-PD1 Treatment

NCT02828098 is registered in ClinicalTrials.gov with Highlight Therapeutics as lead sponsor.

NCT NCT02828098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02828098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory First in Human Phase I Clinical and Pharmacokinetic Study of Intra-tumoral Administration of BO-112 in Adult Patients With Aggressive Solid Tumors, With an Extension Cohort in Combination With Anti-PD1 Treatment
Lead sponsor
Highlight Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2016
Completion date
July 31, 2020
Enrollment
44 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cancer